Latest Content

Protillion Biosciences and AbCellera each secured platform-based drug discovery deals this week, with Protillion partnering with Merck on multi-target protein engineering in a deal worth up to $510 million and Jazz Pharmaceuticals committing up to $84 million upfront to AbCellera for T-cell engaging multispecific antibodies in gastrointestinal cancers.

Brian Hilberdink, president of U.S. Human Pharma, Boehringer Ingelheim, notes how the real obstacle in obesity care isn't how a drug is delivered, it's whether patients stay on treatment long enough to achieve lasting metabolic health.

Behavioral and engagement insights are helping biopharma companies design more personalized patient support programs that improve persistence and long-term outcomes.

Silvia Taylor of Novavax explains how major biotechs like Eli Lilly and Sanofi are developing vaccine strategies for the coming years.

5 Prime Sciences CEO discusses how simply building a massive data set can cause more problems than it solves during clinical trials.

In today's Pharmaceutical Executive Daily, Elicio Therapeutics shares tumble after its Phase II Amplifgy-7P trial of KRAS-targeting immunotherapy ELI-002 7P misses its primary endpoint in adjuvant pancreatic cancer, FDA approves Skinvive by Juvéderm as the first and only hyaluronic acid injectable indicated to reduce neck lines, and Pharmaceutical Executive speaks with Dr. Edward Littler and Dave Watson, the newly paired executive chairman and CEO of Persica Pharmaceuticals, on how they are driving the company's non-opioid pain program PP353 toward Phase III.

FDA has approved Skinvive by Juvéderm as the first hyaluronic acid injectable specifically indicated for neck wrinkles, expanding the Allergan Aesthetics franchise into a new anatomical area.

Elicio Therapeutics' KRAS-targeting immunotherapy ELI-002 7P missed its primary endpoint in a Phase II adjuvant pancreatic cancer trial, sending shares down 47%.

Polaryx’s chief medical officer discusses the regulatory environment for rare, pediatric treatments and how it’s directly impacting clinical trials.

The two executives discuss joining Persica Pharmaceuticals and how they’re driving the company forward with non-opioid pain medication.

Brian Hilberdink, president of U.S. Human Pharma, Boehringer Ingelheim, notes how scale is a starting point, not a finish line, and until clinicians measure what's happening inside the body, obesity treatment will keep falling short of its promise.

In today's Pharmaceutical Executive Daily, Boehringer Ingelheim's Brian Hilberdink argues that obesity innovation must evolve beyond the scale, a pharma regulatory roundup covers two significant FDA approvals, and Pharmaceutical Executive speaks with Raj Indupuri, CEO of eClinical Solutions, on making the ROI case for smarter clinical trials in an era of exploding trial data complexity.

FDA approved two targeted combination regimens this week, clearing AstraZeneca's Truqap as the first biomarker-directed therapy for PTEN-deficient prostate cancer and Merck's Keytruda and Keytruday Qlex plus Welireg.